CANCER remains a critical health challenge in Malaysia. This rising trend highlights the urgent need for effective ...

Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes ...

Akeso has shared for the first time overall survival data from a high-profile Keytruda head-to-head trial for its PD-1xVEGF ...

Keytrda “still reigns” after the interim analysis for Akeso and Summit Therapeutics (SMMT)’ PD-1/VEGF “muddies the outlook” for a potential ivonescimab survival benefit in non-small cell lung cancer.

Citi says the China National Medical Products Administration has just approved ivonescimab in first-line metastatic non-small cell lung cancer ...

Merck (NYSE:MRK) shares inched higher on Friday after Summit Therapeutics (NASDAQ:SMMT) announced the latest survival data ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

A new artificial intelligence (AI) tool could soon help general practitioners (GPs) detect lung cancer in patients up to four ...

A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for ...

BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in ...